Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;40(2):195-207.
doi: 10.1007/s10545-016-0012-4. Epub 2017 Jan 20.

Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature

Affiliations

Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature

D Marques-da-Silva et al. J Inherit Metab Dis. 2017 Mar.

Abstract

Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases caused by defects in glycosylation. Nearly 100 CDG types are known so far. Patients present a great phenotypic diversity ranging from poly- to mono-organ/system involvement and from very mild to extremely severe presentation. In this literature review, we summarize the liver involvement reported in CDG patients. Although liver involvement is present in only a minority of the reported CDG types (22 %), it can be debilitating or even life-threatening. Sixteen of the patients we collated here developed cirrhosis, 10 had liver failure. We distinguish two main groups: on the one hand, the CDG types with predominant or isolated liver involvement including MPI-CDG, TMEM199-CDG, CCDC115-CDG, and ATP6AP1-CDG, and on the other hand, the CDG types associated with liver disease but not as a striking, unique or predominant feature, including PMM2-CDG, ALG1-CDG, ALG3-CDG, ALG6-CDG, ALG8-CDG, ALG9-CDG, PGM1-CDG, and COG-CDG. This review aims to facilitate CDG patient identification and to understand CDG liver involvement, hopefully leading to earlier diagnosis, and better management and treatment.

PubMed Disclaimer

References

    1. J Pediatr. 2005 Dec;147(6):847-50 - PubMed
    1. J Pediatr. 2016 Aug;175:130-136.e8 - PubMed
    1. Mol Genet Metab. 2008 Apr;93(4):444-9 - PubMed
    1. Nat Genet. 2008 Jan;40(1):32-4 - PubMed
    1. Curr Treat Options Neurol. 2016 Aug;18(8):37 - PubMed

Publication types

MeSH terms

LinkOut - more resources